Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report

• There is a critical need for therapeutic options in uterine serous carcinoma (USC). • A substantial proportion of USC cases express estrogen receptors (ER). • This report describes use of letrozole therapy in recurrent, ER-positive USC. • Zoledronic acid may enhance letrozole efficacy against horm...

Descripción completa

Detalles Bibliográficos
Autores principales: Najjar, Omar, Varghese, Aaron, Shahi, Maryam, Vang, Russell, Gaillard, Stephanie, Smith, Thomas, Fader, Amanda N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091228/
https://www.ncbi.nlm.nih.gov/pubmed/32215315
http://dx.doi.org/10.1016/j.gore.2020.100555
_version_ 1783509997761593344
author Najjar, Omar
Varghese, Aaron
Shahi, Maryam
Vang, Russell
Gaillard, Stephanie
Smith, Thomas
Fader, Amanda N.
author_facet Najjar, Omar
Varghese, Aaron
Shahi, Maryam
Vang, Russell
Gaillard, Stephanie
Smith, Thomas
Fader, Amanda N.
author_sort Najjar, Omar
collection PubMed
description • There is a critical need for therapeutic options in uterine serous carcinoma (USC). • A substantial proportion of USC cases express estrogen receptors (ER). • This report describes use of letrozole therapy in recurrent, ER-positive USC. • Zoledronic acid may enhance letrozole efficacy against hormone-sensitive tumors. • Aromatase inhibitors could be a potential treatment option in ER-positive USC.
format Online
Article
Text
id pubmed-7091228
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70912282020-03-25 Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report Najjar, Omar Varghese, Aaron Shahi, Maryam Vang, Russell Gaillard, Stephanie Smith, Thomas Fader, Amanda N. Gynecol Oncol Rep Case Report • There is a critical need for therapeutic options in uterine serous carcinoma (USC). • A substantial proportion of USC cases express estrogen receptors (ER). • This report describes use of letrozole therapy in recurrent, ER-positive USC. • Zoledronic acid may enhance letrozole efficacy against hormone-sensitive tumors. • Aromatase inhibitors could be a potential treatment option in ER-positive USC. Elsevier 2020-03-02 /pmc/articles/PMC7091228/ /pubmed/32215315 http://dx.doi.org/10.1016/j.gore.2020.100555 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Najjar, Omar
Varghese, Aaron
Shahi, Maryam
Vang, Russell
Gaillard, Stephanie
Smith, Thomas
Fader, Amanda N.
Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
title Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
title_full Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
title_fullStr Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
title_full_unstemmed Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
title_short Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
title_sort aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091228/
https://www.ncbi.nlm.nih.gov/pubmed/32215315
http://dx.doi.org/10.1016/j.gore.2020.100555
work_keys_str_mv AT najjaromar aromataseinhibitortherapyinrecurrentestrogenreceptorpositiveuterineserouscarcinomaacasereport
AT vargheseaaron aromataseinhibitortherapyinrecurrentestrogenreceptorpositiveuterineserouscarcinomaacasereport
AT shahimaryam aromataseinhibitortherapyinrecurrentestrogenreceptorpositiveuterineserouscarcinomaacasereport
AT vangrussell aromataseinhibitortherapyinrecurrentestrogenreceptorpositiveuterineserouscarcinomaacasereport
AT gaillardstephanie aromataseinhibitortherapyinrecurrentestrogenreceptorpositiveuterineserouscarcinomaacasereport
AT smiththomas aromataseinhibitortherapyinrecurrentestrogenreceptorpositiveuterineserouscarcinomaacasereport
AT faderamandan aromataseinhibitortherapyinrecurrentestrogenreceptorpositiveuterineserouscarcinomaacasereport

Ejemplares similares